Business

mass. movers

Alnylam reports early success with drug

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Globe File photo/2013

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Advertisement

Alnylam Pharmaceuticals Inc. stock climbed after the Cambridge company reported positive early trial results for an experimental RNA interference drug, ALN-TTRsc. It’s designed to treat transthyretin familial amyloidosis, a rare genetic condition in which a starchy protein builds up in organs and tissues. ALN-TTRsc was evaluated for a form of the disease typically treated with a liver transplant. Alnylam will start a late-stage trial of the drug in 2014. It’s developing the drug in partnership with Genzyme.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com